Top

Diabetologia

Published in:

01-07-2008 | Article

Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways

Authors: Q. Wang, H. Heimberg, D. Pipeleers, Z. Ling

Published in: Diabetologia | Issue 7/2008

Abstract

Aims/hypothesis

Prolonged exposure of rat beta cells to the insulin secretagogue glibenclamide has been found to induce a sustained increase in basal insulin synthesis. This effect was calcium-dependent and localised in cells that had been degranulated by the drug. Since it was blocked by the translation inhibitor cycloheximide, we examined whether sustained exposure to glibenclamide activates translational factors by calcium-dependent signalling pathways.

Methods

Purified rat beta cells were cultured with and without glibenclamide in the presence or absence of inhibitors of calcium-dependent signalling pathways before measurement of basal and stimulated protein and insulin synthesis, and assessment of abundance of (phosphorylated) translation factors.

Results

A 24 h exposure to glibenclamide induced activation of four translation factors, i.e. phosphorylation of eukaryotic initiation factor (eIF) 4e binding protein 1 and ribosomal protein S6 (rpS6), and dephosphorylation of eIF-2α and eukaryotic elongation factor 2. The rise in phospho-rpS6 intensity was localised to a subpopulation of beta cells with low insulin content. This activation of translational factors and the associated elevation of insulin synthesis were completely blocked by the calcium channel blocker verapamil and partially blocked by the mammalian target of rapamycin (mTOR) inhibitor rapamycin, the protein kinase A (PKA) inhibitor Rp-8-Br-cAMPs and the mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase (MEK) inhibitor U0126; a combination of inhibitors exhibited additive effects.

Conclusions/interpretation

Prolonged exposure to glibenclamide activates protein translation in pancreatic beta cells through the calcium-regulated mTOR, PKA and MEK signalling pathways. The observed intercellular differences in translation activation are proposed as underlying mechanism for functional heterogeneity in the pancreatic beta cell population.

Pipeleers D, Kiekens R, Ling Z, Wilikens A, Schuit F (1994) Physiologic relevance of heterogeneity in the pancreatic beta-cell population. Diabetologia 37(Suppl 2):S57–S64PubMedCrossRef

Ling Z, Kiekens R, Mahler T et al (1996) Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells. Diabetes 45:1774–1782PubMedCrossRef

Ling Z, Wang Q, Stange G, In’t Veld P, Pipeleers D (2006) Glibenclamide treatment recruits beta-cell subpopulation into elevated and sustained basal insulin synthetic activity. Diabetes 55:78–85PubMedCrossRef

Yamato E, Ikegami H, Tahara Y et al (1994) Glyburide enhances insulin gene expression and glucose-induced insulin release in isolated rat islets. Biochem Biophys Res Commun 199:327–333PubMedCrossRef

Yamato E, Ikegami H, Tahara Y et al (1993) Cellular mechanism of glyburide-induced insulin gene expression in isolated rat islets. Biochem Biophys Res Commun 197:957–964PubMedCrossRef

Guiot Y, Henquin JC, Rahier J (1994) Effects of glibenclamide on pancreatic beta-cell proliferation in vivo. Eur J Pharmacol 261:157–161PubMedCrossRef

Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML (2006) Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem 281:3261–3267PubMedCrossRef

Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML (2004) Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 53(Suppl 3):S225–S232PubMedCrossRef

Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807–826PubMedCrossRef

10.

Proud CG (2007) Signaling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403:217–234PubMedCrossRef

11.

Proud CG (2005) eIF2 and the control of cell physiology. Semin Cell Dev Biol 16:3–12PubMedCrossRef

12.

Xu G, Marshall CA, Lin TA et al (1998) Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation. J Biol Chem 273:4485–4491PubMedCrossRef

13.

Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477–480PubMedCrossRef

14.

Meyuhas O (2000) Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 267:6321–6330PubMedCrossRef

15.

Browne GJ, Proud CG (2002) Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269:5360–5368PubMedCrossRef

16.

Hershey JWB, Merrick WC (2000) The pathway and mechanism of initiation of protein synthesis. In: Sonenberg N, Mathews MB, Hershey JWB (eds) Translational control of gene expression, 2nd edn. Cold Spring Harbor Laboratory Press, New York, pp 33–88

17.

McDaniel ML, Marshall CA, Pappan KL, Kwon G (2002) Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. Diabetes 51:2877–2885PubMedCrossRef

18.

Kleijn M, Scheper GC, Voorma HO, Thomas AA (1998) Regulation of translation initiation factors by signal transduction. Eur J Biochem 253:531–544PubMedCrossRef

19.

Pipeleers DG, in’t Veld PA, Van de Winkel M, Maes E, Schuit FC, Gepts W (1985) A new in vitro model for the study of pancreatic A and B cells. Endocrinology 117:806–816PubMedCrossRef

20.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506PubMedCrossRef

21.

Schuit FC, Kiekens R, Pipeleers DG (1991) Measuring the balance between insulin synthesis and insulin release. Biochem Biophys Res Commun 178:1182–1187PubMedCrossRef

22.

Martens GA, Wang Q, Kerckhofs K, Stange G, Ling Z, Pipeleers D (2006) Metabolic activation of glucose low-responsive beta-cells by glyceraldehyde correlates with their biosynthetic activation in lower glucose concentration range but not at high glucose. Endocrinology 147:5196–5204PubMedCrossRef

23.

Lehtihet M, Welsh N, Berggren PO, Cook GA, Sjoholm A (2003) Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab 285:E438–E446PubMed

24.

Ball AJ, McCluskey JT, Flatt PR, McClenaghan NH (2004) Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components. Pharmacol Res 50:41–46PubMedCrossRef

25.

Shi H, Moustaid-Moussa N, Wilkison WO, Zemel MB (1999) Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J 13:1833–1838PubMed

26.

Jaber LA, Antal EJ, Slaughter RL, Welshman IR (1994) Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. Diabetes Care 17:1300–1306PubMedCrossRef

27.

Rydberg T, Jonsson A, Karlsson MO, Melander A (1997) Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 43:373–381PubMedCrossRef

28.

Proks P, Reimann F, Green N, Gribble F, Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51(Suppl 3):S368–S376PubMedCrossRef

29.

Sturgess NC, Ashford ML, Cook DL, Hales CN (1985) The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 2:474–475PubMedCrossRef

30.

Anello M, Gilon P, Henquin JC (1999) Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca²⁺ regulation prevail over changes in insulin content. Br J Pharmacol 127:1883–1891PubMedCrossRef

31.

Ballou LM, Jiang YP, Du G, Frohman MA, Lin RZ (2003) Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling. FEBS Lett 550:51–56PubMedCrossRef

32.

Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF (2006) Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB J 20:466–475PubMedCrossRef

33.

Yano S, Tokumitsu H, Soderling TR (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:584–587PubMedCrossRef

34.

Avruch J, Lin Y, Long X, Murthy S, Ortiz-Vega S (2005) Recent advances in the regulation of the TOR pathway by insulin and nutrients. Curr Opin Clin Nutr Metab Care 8:67–72PubMedCrossRef

35.

Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803PubMedCrossRef

36.

Lang CH, Frost RA (2007) Sepsis-induced suppression of skeletal muscle translation initiation mediated by tumor necrosis factor alpha. Metabolism 56:49–57PubMedCrossRef

37.

Gomez E, Powell ML, Greenman IC, Herbert TP (2004) Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha. J Biol Chem 279:53937–53946PubMedCrossRef

38.

Redpath NT, Price NT, Severinov KV, Proud CG (1993) Regulation of elongation factor-2 by multisite phosphorylation. Eur J Biochem 213:689–699PubMedCrossRef

39.

Diggle TA, Redpath NT, Heesom KJ, Denton RM (1998) Regulation of protein-synthesis elongation-factor-2 kinase by cAMP in adipocytes. Biochem J 336(Pt 3):525–529PubMed

40.

Hovland R, Eikhom TS, Proud CG et al (1999) cAMP inhibits translation by inducing Ca²⁺/calmodulin-independent elongation factor 2 kinase activity in IPC-81 cells. FEBS Lett 444:97–101PubMedCrossRef

41.

Straub SG, Sharp GW (2002) Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 18:451–463PubMedCrossRef

42.

Nesher R, Anteby E, Yedovizky M, Warwar N, Kaiser N, Cerasi E (2002) Beta-cell protein kinases and the dynamics of the insulin response to glucose. Diabetes 51(Suppl 1):S68–S73PubMedCrossRef

43.

Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751–1760PubMedCrossRef

44.

Wang X, Flynn A, Waskiewicz AJ et al (1998) The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 273:9373–9377PubMedCrossRef

45.

Banko JL, Hou L, Klann E (2004) NMDA receptor activation results in PKA- and ERK-dependent Mnk1 activation and increased eIF4E phosphorylation in hippocampal area CA1. J Neurochem 91:462–470PubMedCrossRef

46.

Itoh N, Okamoto H (1980) Translational control of proinsulin synthesis by glucose. Nature 283:100–102PubMedCrossRef

47.

Yan L, Nairn AC, Palfrey HC, Brady MJ (2003) Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells. J Biol Chem 278:18177–18183PubMedCrossRef

48.

Alarcon C, Wicksteed B, Rhodes CJ (2006) Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 49:2920–2929PubMedCrossRef

49.

Schatz H, Maier V, Hinz M, Nierle C, Pfeiffer EF (1972) The effect of tolbutamide and glibenclamide on the incorporation of (3 H)leucine and on the conversion of proinsulin to insulin in isolated pancreatic islets. FEBS Lett 26:237–240PubMedCrossRef

50.

Gorus FK, Schuit FC, In’t Veld PA, Gepts W, Pipeleers DG (1988) Interaction of sulfonylureas with pancreatic beta-cells. A study with glyburide. Diabetes 37:1090–1095PubMedCrossRef

Title: Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways
Authors: Q. Wang
H. Heimberg
D. Pipeleers
Z. Ling
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 7/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-008-1026-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 7/2008

Insulin may have a role to play in protecting beta cells from deterioration in diabetes. Reply to Del Parigi A [letter]

Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study

Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery

Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome

Insulin may have a role to play in protecting beta cells from deterioration in diabetes

Cerebral perfusion in relation to cognitive function and type 2 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page